PL2861573T3 - Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe - Google Patents
Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworoweInfo
- Publication number
- PL2861573T3 PL2861573T3 PL13734162T PL13734162T PL2861573T3 PL 2861573 T3 PL2861573 T3 PL 2861573T3 PL 13734162 T PL13734162 T PL 13734162T PL 13734162 T PL13734162 T PL 13734162T PL 2861573 T3 PL2861573 T3 PL 2861573T3
- Authority
- PL
- Poland
- Prior art keywords
- antibacterial
- anticancer agents
- oxathiazine
- derivatives
- oxathiazine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/10—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms two oxygen atoms and one sulfur atom, e.g. cyclic sulfates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661092P | 2012-06-18 | 2012-06-18 | |
| US201261694452P | 2012-08-29 | 2012-08-29 | |
| EP13734162.4A EP2861573B1 (en) | 2012-06-18 | 2013-06-17 | Oxathiazine derivatives as antibacterial and anticancer agents. |
| PCT/IB2013/001261 WO2013190355A1 (en) | 2012-06-18 | 2013-06-17 | Oxathiazine derivatives as antibacterial and anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2861573T3 true PL2861573T3 (pl) | 2018-02-28 |
Family
ID=48746589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13734162T PL2861573T3 (pl) | 2012-06-18 | 2013-06-17 | Pochodne oksatiazyny jako środki przeciwbakteryjne i przeciwnowotworowe |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9241943B2 (pl) |
| EP (1) | EP2861573B1 (pl) |
| DK (1) | DK2861573T3 (pl) |
| ES (1) | ES2644870T3 (pl) |
| HU (1) | HUE034822T2 (pl) |
| PL (1) | PL2861573T3 (pl) |
| PT (1) | PT2861573T (pl) |
| WO (1) | WO2013190355A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9241943B2 (en) * | 2012-06-18 | 2016-01-26 | Geistlich Pharma Ag | Oxathiazine derivatives as antibacterial and anticancer agents |
| CN110776479A (zh) * | 2014-12-19 | 2020-02-11 | 盖斯特里希医药公司 | *噻嗪样化合物、其制备方法和用途 |
| US11591302B2 (en) | 2014-12-19 | 2023-02-28 | Geistlich Pharm A Ag | Processes for preparing oxathiazin-like compounds |
| US20190381060A1 (en) | 2016-01-11 | 2019-12-19 | Cormedix Inc. | Taurolidine treatment for myc-expressing tumors in mammalian bodies |
| US11541061B2 (en) | 2016-01-11 | 2023-01-03 | Cormedix Inc. | Neuroblastoma treatment with taurolidine hydrolysis products |
| JP6933659B2 (ja) * | 2016-03-18 | 2021-09-08 | ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ | トリプルネガティブ乳癌の治療方法 |
| JP6913692B2 (ja) | 2016-04-07 | 2021-08-04 | ガイストリッヒ・ファルマ・アーゲーＧｅｉｓｔｌｉｃｈ Ｐｈａｒｍａ Ａｇ | オキサチアジン様化合物を作製する方法 |
| US10815194B2 (en) * | 2016-11-14 | 2020-10-27 | Byondis B.V. | Process for the preparation of mono-protected α,ω-diamino alkanes |
| CN113164491A (zh) * | 2018-08-28 | 2021-07-23 | 科医公司 | 用于治疗幼年哺乳动物体内神经母细胞瘤的方法和组合物 |
| CN114096255B (zh) * | 2019-05-22 | 2024-09-10 | 盖斯特里希医药公司 | 用于治疗、预防、抑制或减少细胞因子释放的噁噻嗪二氧化物 |
| AU2022267897A1 (en) * | 2021-04-29 | 2023-11-02 | Geistlich Pharma Ag | Antimicrobial and anticancer agents |
| WO2024028846A1 (en) * | 2022-08-05 | 2024-02-08 | Geistlich Pharma Ag | Combination therapy for treating cancers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1160443B (de) * | 1961-11-30 | 1964-01-02 | Hoechst Ag | Verfahren zur Herstellung von Tetrahydro-oxathiazin-dioxyden |
| DE1234988B (de) | 1964-11-28 | 1967-02-23 | Bayer Ag | Verfahren zur Herstellung von Copolymerisaten des Trioxans |
| GB8617482D0 (en) | 1986-07-17 | 1986-08-28 | Geistlich Soehne Ag | Pharmaceutical composition |
| US6117868A (en) | 1998-09-16 | 2000-09-12 | Ed. Geistlich Sohne Ag Fur Chemische Industrie | Treatment of gastrointestinal ulcers or gastritis caused by microbial infection |
| CA2696185C (en) | 1999-12-06 | 2014-09-23 | Geistlich Pharma Ag | Use of taurolidine and derivatives thereof in the treatment of cancer by induction of apoptosis |
| US9241943B2 (en) * | 2012-06-18 | 2016-01-26 | Geistlich Pharma Ag | Oxathiazine derivatives as antibacterial and anticancer agents |
-
2013
- 2013-06-17 US US14/409,352 patent/US9241943B2/en active Active
- 2013-06-17 HU HUE13734162A patent/HUE034822T2/en unknown
- 2013-06-17 WO PCT/IB2013/001261 patent/WO2013190355A1/en active Application Filing
- 2013-06-17 PT PT137341624T patent/PT2861573T/pt unknown
- 2013-06-17 ES ES13734162.4T patent/ES2644870T3/es active Active
- 2013-06-17 PL PL13734162T patent/PL2861573T3/pl unknown
- 2013-06-17 EP EP13734162.4A patent/EP2861573B1/en active Active
- 2013-06-17 DK DK13734162.4T patent/DK2861573T3/da active
-
2015
- 2015-12-03 US US14/958,225 patent/US9624187B2/en active Active
-
2017
- 2017-03-29 US US15/472,550 patent/US9844555B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2644870T3 (es) | 2017-11-30 |
| US20160159759A1 (en) | 2016-06-09 |
| US9844555B2 (en) | 2017-12-19 |
| US9624187B2 (en) | 2017-04-18 |
| DK2861573T3 (da) | 2017-11-13 |
| EP2861573B1 (en) | 2017-08-30 |
| US9241943B2 (en) | 2016-01-26 |
| US20150182534A1 (en) | 2015-07-02 |
| WO2013190355A1 (en) | 2013-12-27 |
| US20170196876A1 (en) | 2017-07-13 |
| EP2861573A1 (en) | 2015-04-22 |
| PT2861573T (pt) | 2017-11-14 |
| HUE034822T2 (en) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201506880B (en) | Quinolines derivatives as novel anticancer agents | |
| HK1203927A1 (en) | Heterocyclic compounds and uses as anticancer agents | |
| PT2861573T (pt) | Derivados de oxatiazina como agentes antibacterianos e anticancerígeno | |
| IL233863A (en) | Pyridine derivatives, preparations containing them and their uses | |
| GB201304967D0 (en) | . | |
| IL237068A (en) | 1,3-dioxanomorphides and 1,3-dioxanocodides | |
| GB201204183D0 (en) | . | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| EP3016716A4 (en) | Anticancer combinations | |
| EP2822558A4 (en) | PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | |
| HK1203811A1 (en) | Anticancer agent | |
| HK1198833A1 (en) | N-acylpeptide derivatives and their uses n- | |
| EP2873701A4 (en) | ORGANIC-INORGANIC COMPLEX, AND COMPOSITION FOR THE FORMATION OF SAID COMPLEX | |
| EP2903979A4 (en) | Novel compounds, their preparation and use | |
| HK1207317A1 (en) | Substituted 1,6-naphthyridines 16- | |
| IL238452A0 (en) | History of new modified 4,1-dithienes and their use as fungicides | |
| EP2864362A4 (en) | ANTICANCER TREATMENT | |
| EP2832346A4 (en) | AQUEOUS DISPERSED COMPOSITION | |
| IL233682A0 (en) | Modified phenylazole derivatives, preparations containing them and their uses | |
| EP2837387A4 (en) | ANTICANCER AGENT | |
| HK1200821A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators gpbar1 12-16-- | |
| GB201603522D0 (en) | Pyrazolochalcones as potential anticancer agents | |
| EP2915536A4 (en) | ANTICROBREAM AND COMBINATION WITH THE ANTICREMENT | |
| GB201214551D0 (en) | Anticancer treatment | |
| GB201218175D0 (en) | Anticancer treatments |